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Abstract
Background: Haploinsufficiency of TAB2 is known to cause congenital heart
defects and cardiomyopathy due to its important roles in cardiovascular tissue,
both during development and through adult life. We report a sibling pair display-
ing adult-onset cardiomyopathy, hypermobility, and mild myopia. Our proband, a
39-year-old male, presents only with the above symptoms, while his 36-year-old
sister was also notable for a ventricular septal defect in her infancy.
Methods: Whole-exome sequencing was utilized to identify the molecular basis
of the phenotype found in two siblings. A molecular modeling technique that
takes advantage of conformational sampling advances (Maxwell’s demon molecu-
lar dynamics and Monte Carlo) were used to make a model of the mutant variant
for comparative analytics to the wild-type.
Results: Exome sequencing revealed a novel, heterogeneous pathogenic variant
in TAB2, c.1039 C>T (p.R347X), that was present in both individuals. This
pathogenic variant removes just over half the residues from the TAB2 protein and
severely impacts its functional ability, which we describe in detail.
Conclusions: Analysis of the proband’s family showed a history of cardiomyopa-
thy, but no congenital heart defects or connective tissue disease. We highlight the
heterogeneity in phenotype of TAB2 pathogenic variants and confirm the
pathogenicity of this new variant through neoteric protein modeling techniques.
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1 | INTRODUCTION
TGF-beta activated kinase 1/MAP3K7 binding protein 2
(TAB2) is a protein encoded by TAB2, a gene located
on chromosome 6q25.1 [OMIM #605101]. This pro-
tein serves a function in linking MAP3K7 and TNF
receptor-associated factor 6 (TRAF6) in the interleukin-1
(IL1) signaling pathway, and is used in the activation of
c-Jun N-terminal kinases (JNK) and nuclear factor kappa-B
(NFKB) (Takaesu et al., 2000). Research by Thienpont
et al. (2010) has demonstrated that TAB2 is also expressed
in embryonic cardiac tissue in both humans and zebrafish.
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Knockdown of TAB2 expression in zebrafish embryos
caused delays in epiboly and convergent extension defects
during gastrulation (around 12 hr postfertilization), ulti-
mately resulting in significant heart failure around 36–
48 hr postfertilization. Similarities in TAB2 expression
between humans and zebrafish at this stage of develop-
ment, and the presence of 2 patients in an analyzed group
with cardiac outflow tract defects and pathogenic missense
variants in TAB2, prompted the researchers to conclude that
haploinsufficiency of TAB2 can cause congenital heart
defects in humans (Thienpont et al., 2010). This conclusion
is supported by additional reports detailing patients with
pathogenic deletions or missense variants in TAB2 leading
to congenital heart defects, among other symptoms (Ritelli
et al., 2018; Weiss, Applegate, Wang, & Batista, 2015).
In this report, we present two siblings having a novel,
heterozygous nonsense pathogenic variant in TAB2,
denoted c.1039 C>T (p.R347X). This variant creates a pre-
mature stop codon at residue 347 of the TAB2 protein and
entirely removes its MAP3K7-binding C-terminal domain
(Takaesu et al., 2000). The resulting TAB2 variant likely
interferes with proper IL1 signaling as a consequence, in
addition to causing congenital heart defects in the siblings.
We support this theory with novel protein molecular mod-
eling techniques. Additionally, we discuss the patient’s
unique variant in TAB2, comparing his symptoms and fam-
ily history to those of existing cases.
1.1 | Case presentation
Our proband is a 39-year-old male who was first seen in
our clinic at age 35. In his early medical history, he reports
that he was hypermobile (Beighton score of 7/9), small in
stature, and had a high-arched palate. He has had several
joint dislocations involving the digits and patellae, the first
of which occurred around 12–14 years old. Due to family
history including cardiomyopathy in three paternal uncles,
father, and sister, the proband was investigated by a cardi-
ologist at 16 years old. No heart problems were found,
though his other symptoms were suggestive of an underly-
ing connective tissue disorder and he was labeled as having
“either Ehlers–Danlos or Loeys–Dietz syndrome.” Years
later, the proband was found with a pulmonary artery
aneurysm after he was hospitalized for a spontaneous pneu-
mothorax in 2008. The proband was closely followed after
this incident due to a worsening of the aneurysm and sev-
ere pulmonic regurgitation (PR).
At age 35, the proband’s pulmonary artery aneurysm
had grown to 5.7 cm. Aside from his severe PR, he was
experiencing moderate mitral regurgitation, mild tricuspid
regurgitation, severe left atrial enlargement, and biventricu-
lar failure with an ejection fraction of 22%. Surgery was
now necessary. A pulmonary artery resection with
pulmonary homograft valve 27 mm implantation was per-
formed with resultant symptomatic improvement and an
improved ejection fraction to 45%. The surgeons had noted
myxoid degeneration in the pulmonary valve, supporting
the presence of a connective tissue disorder. At age 37 he
was found to have gallbladder stones and underwent a
laparoscopic cholecystectomy. Days after the surgery, he
returned to the hospital with acute respiratory distress,
shortness of breath, and fever. Investigations revealed he
had contracted Klebsiella pneumonia. He was hospitalized
once again, and developed acute liver failure, acute renal
failure, and respiratory failure requiring ventilator support,
acute-on-chronic systolic heart failure, and pulmonary
artery hypertension. The proband returned home after his
multiorgan system failure had subsided, though he later
experienced dyspnea and exercise intolerance. Pulmonary
function tests were performed and found he had reduced
left lung volume with restrictive disease of unknown etiol-
ogy. This finding, along with his existing connective tissue
disorder and pulmonary artery aneurysm, led to the pro-
band being referred to medical genetics with suspicion of
Loeys–Dietz syndrome.
During a genetics consultation, the proband agreed to
multigene panels for thoracic aortic aneurysm and dissec-
tion and cardiomyopathy. The tests were negative, finding
no pathogenic variants related to Loeys–Dietz, Ehlers–Dan-
los, or Marfan syndrome. As a next step, whole-exome
sequencing (WES) and mtDNA analysis were performed.
WES uncovered the likely pathogenic variant c.1039 C>T
(p.R347X) in TAB2 in a heterozygous state, which we pro-
pose is responsible for the symptoms seen in the patient.
This variant inserts a stop codon near the middle of the
protein, resulting in TAB2 truncation and dysfunction.
Knowing of the likely pathogenic variant afflicting our
proband, his sister was evaluated as well. She is a 36-year-
old female who had a ventricular septal defect that was
repaired in her infancy, right bundle branch and atrioven-
tricular block, right ventricular dilation and diminished RV
function, mild dilation of the aortic root, hypermobility
(Beighton 5/9), unilateral sensorineural hearing loss, myo-
pia, and mildly sloped shoulders. The similarity of her phe-
notype to the proband’s was not a coincidence, as she was
found to have the same TAB2 variant. Probands mother
was negative for the familial variant, suggesting likely
paternal inheritance.
In the time since the proband’s genetic testing, he has
continued to follow with the cardiology clinic. EKG shows
severe biventricular enlargement, an LV ejection fraction of
33%, a right bundle block, enlarged atria (the right more
severely so), and mild aortic and mitral valve regurgitation.
He developed brief episodes of chest pain, neck swelling
with underlying lymphadenopathies, and volume overload.
His pulmonary valve regurgitation and pulmonary artery
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aneurysm have worsened since his surgery at age 35, with
the aneurysm reaching 5.2 cm. These symptoms prompted
his placement on the cardiac transplantation list at age 39.
The proband has been considered for a percutaneous pul-
monary valve replacement or some form of mechanical cir-
culatory support including a left ventricular assist device
(LVAD), biventricular assist device (BIVAD), or total arti-
ficial heart while he waits for a transplant.
2 | MATERIALS AND METHODS
2.1 | Ethical compliance
Standard evidence-based medical care was followed in
treating the patient in this case and all procedures followed
were in accordance with the ethical standards of the
responsible committee on human experimentation (institu-
tional and national) and with the Helsinki Declaration of
1975, as revised in 2000 (5). Written informed consent for
genetic analysis and all other testing was obtained from the
patient and his sister. Specific ethical approval was not
sought for this case report.
2.2 | Molecular modeling
The sequence of human TGF-beta-activated kinase 1 and
MAP3K7-binding protein 2 (known as TAB2), a protein
encoded by TAB2 gene, was taken from the NCBI Refer-
ence Accession Sequence: NM_001292034: version NM_
001292034.2, which is encoded for the amino acid
sequence; and was used for computer assisted modeling.
Monte Carlo simulations were performed on the mutant to
allow local regional changes for full-length 693 amino
acids and when the p.R347X variant was introduced. We
modeled this protein with the assumption that it could
potentially be translated as a partially folded protein.
The X-ray refinement for Monte Carlo was built using
YASARA SSP/PSSM Method (Altschul et al., 1997;
Hooft, Sander, Scharf, & Vriend, 1996; Hooft, Vriend,
Sander, & Abola, 1996; King & Sternberg, 1996; Krieger
et al., 2009; Qiu & Elber, 2006). The structure was
relaxed to the YASARA/Amber force field using knowl-
edge-based potentials within YASARA. The side chains
and rotamers were adjusted with knowledge-based poten-
tials, simulated annealing with explicit solvent, and small
equilibration simulations using YASARA’s refinement
protocol (Laskowski, MacArthur, Moss, & Thornton,
1993). The entire full-length structure was modeled, filling
in any gaps or unresolved portions from the X-ray.
Refinement of the finalized models was completed using
either Schrodinger’s LC-MOD Monte Carlo-based
(Altschul et al., 1997; Hooft et al., 1996, 1996; Krieger
et al., 2009) (Videos S1–S3).
Monte Carlo (MC) dynamics searching (MC search or
Maxwell’s demon molecular dynamics [MdMD]) was com-
pleted on each model for conformational sampling, using
methods previously described in the literature (Caulfield,
2011; Caulfield & Devkota, 2012; Caulfield, Devkota, &
Rollins, 2011; Caulfield & Medina-Franco, 2011). Briefly,
each TAB2 variant system was minimized with relaxed
restraints using either Steepest Descent or Conjugate Gradi-
ent PR, then allowed to undergo the MC search criteria, as
shown in the literature (Caulfield, 2011; Caulfield & Dev-
kota, 2012; Caulfield & Medina-Franco, 2011; Caulfield
et al., 2011). The primary purpose of MC, in this scenario,
is examining any conformational variability that may occur
with different mutations in the region near to the mutation
and possible effect on DNA binding or processing with
TAB2.
3 | RESULTS
3.1 | MdMD, MC conformational searches,
and free energy calculations
Following the conformational sampling from MdMD and
MC simulations for protein structure refolding, we calcu-
lated the free energy differences on a per residue basis and
examined the effect on electrostatic surface. For WT versus
the truncation variant p.R347X, we found the stability of
the object from energetic calculations for DG per amino
acid to remain relatively the same, such that WT and
p.R347X were 0.954 and 0.951 kcal/aa*mol*A2, respec-
tively (Caulfield, 2011; Caulfield & Devkota, 2012; Caul-
field & Medina-Franco, 2011; Lopez-Vallejo et al., 2011;
Reumers et al., 2005; Schymkowitz et al., 2005; Zhang
et al., 2013). This object stability did not indicate any
changes in structure that were deleterious to function from
immediate inspection, which the mutation foldx algorithm
can provide. Thus we examined the local residues and
determined an electrostatic calculation may be useful to
explain the change in function. The molecular model for
the full structure and its truncated form are given (Figure 1,
Videos S1–S3) using our established state-of-the-art meth-
ods (Abdul-Hay et al., 2013; Ando et al., 2017; Caulfield,
2011; Caulfield & Devkota, 2012; Caulfield, Fiesel, &
Springer, 2015; Caulfield & Medina-Franco, 2011; Caul-
field et al., 2011, 2014; Fiesel et al., 2015, 2015; Lopez-
Vallejo et al., 2011; Puschmann et al., 2017; Zhang et al.,
2013).
Local residues within the 12A cutoff near the “cleav-
age” site include Phe137, Asn138, Phe140, Ile389, Thr366,
Ser233, Val387, and Thre366, which tend to locate near
the two domain halves found in the N-terminus and C-ter-
minus lobes (Figures 1 and 2a,b). The N-terminus lobe has
four interesting amino acids involved in C-terminus
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interactions in addition to the R347 residue, which includes
Phe137, Asn138, Phe140, and Ser233. The residues from
the C-terminus side that are interacting with the N-terminus
lobe include residues Thr366, His678, Pro679, and Leu681
(Figure 2b).
Mapping electrostatics was accomplished using the
Poisson–Boltzmann calculation for solvation on the entire
693 amino acid structure and the 347 amino acid structure.
The effects of the changes were strongly pronounced on
electrostatic distribution with a+3 KT/E cutoff for both.
The WT particle (all 693 aa) has a distributed electrostatic
charge that is both positive and negative and has zones
between the two domains that hold together (N-terminus
interface is negative and C-terminus interface is positive),
which would only be perturbed by a competitive protein
binder or substrate (Figure 2a). The p.R347X particle is
predominately negative in charge distribution by compar-
ison (Figure 2c). This could account for lowering its inter-
action potential with partner proteins in its pathway
(Caulfield, 2011; Caulfield & Devkota, 2012; Caulfield &
Medina-Franco, 2011; Lopez-Vallejo et al., 2011; Reumers
et al., 2005; Schymkowitz et al., 2005; Zhang et al., 2013).
4 | DISCUSSION
TAB2 serves an important function both in the IL1 signal-
ing pathway and in embryonic development of cardiac tis-
sue (Takaesu et al., 2000; Thienpont et al., 2010).
Pathogenic variants or haploinsufficiency of this gene leads
to dysfunctional TAB2, which often has reduced MAP3K7
or TRAF6 binding ability (Weber, Wasiliew, & Kracht,
2010). Inability to bind these molecules results in lower
expression of NFKB, which in turn favors cell necrosis
over survival in cardiac tissue and often causes cardiomy-
opathy (Cheng et al., 2017). Deletions and pathogenic vari-
ants in TAB2 can also cause haploinsufficiency in the
embryonic stage of life, resulting in congenital heart
defects (Thienpont et al., 2010). While it is true that not all
individuals with deficiencies in TAB2 will experience con-
genital heart defects, many will experience cardiomyopathy
or heart disease at some point in their lives (Cheng et al.,
2017). Patients known to have a family history of congeni-
tal heart defects should be wary of this despite a potential
lack of problems in childhood.
The pathogenic variant shared by our sibling pair,
c.1039 C>T (p.R347X), has a variable phenotype which
includes congenital heart defects and adult-onset cardiomy-
opathy. As we noted before, the proband’s sister had a ven-
tricular septal defect as an infant which was surgically
repaired. Conversely, the proband had no heart problems as
a child and was informed by his cardiologist at 16 years
old that he “likely would not need to return.” Despite this
difference, both individuals ultimately developed similar
symptoms of cardiomyopathy, including aortic/pulmonary
arterial dilation, dilation of the ventricles, and conduction
disease noted by a right branch bundle block. Additionally,
these symptoms varied in severity between the two individ-
uals. The proband has had persistent symptoms despite his
homograft and is now awaiting heart transplant, while his
sister has not required surgical correction since infancy,
demonstrating inconsistent expression even within a sibling
FIGURE 1 TAB2 molecular model for full-length human sequence consisting of 693 amino acids and the truncation variant p.R347X. (a)
Full-length model for the entire TAB2 structure that shows two clear domains separated around amino acid 350–360, where R347 plays a role in
interacting between the two domains. (b) Rotation of the full-length model by 90° in X-axis to better show the domains. (c) Zoom into the region
around Arg347 and how the folded protein has Met1 and Phe693 folded within 35A of each other. (d) Truncated TAB2 at R347X, showing
smaller N-terminus domain lobe. (e) Zoom into the N-terminus domain lobe with residues within 12 A of R347 shown and labeled. All protein
ribbons are colored by secondary structure and residues shown in licorice rendering and using standard element coloring (C-gray, O-red, N-blue,
H-white, S-yellow) except for the highlighted residues (Met1-green carbons, Arg347-purple carbons, Phe693-orange carbons)
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pair. The proband also displays more cardiac issues overall
than his sister, who did not have valve regurgitation or
myxoid degeneration of valves. Both siblings were notable
for hypermobility, which has been well recognized in pre-
vious literature (Cheng et al., 2017; Ritelli et al., 2018).
Both exhibited mild myopia, which has been recorded in
one individual who coincidentally also has a pathogenic
nonsense variant in TAB2, although this may well be multi-
factorial (Ritelli et al., 2018). The sloping shoulders seen
in the sister and high-arched palate seen in the proband
seem to be unique features.
The molecular modeling from comparison of the wild-
type and variant indicates the natural stabilization induced
by residues Phe137, Asn138, Phe140, Arg347 interacting
directly with His678, Pro679, and Leu681, which are lost
in variant p.R347X. Additionally, residue Thr366 interacts
with both the N-terminus and C-terminus regions and we
propose that any mutation of Thr366 (Ala, Gly, or Pro)
would be useful screen for loss of function (lowered func-
tion) in TAB2 functional studies.
Through observation of the proband’s extended family,
we gain further support for the heterogeneous phenotype
associated with his pathogenic variant of TAB2 (Figure 3).
Three of the proband’s paternal uncles, his father, and his sis-
ter presented with cardiomyopathy. He shares his symptoms
of hypermobility with his father and sister. During the pro-
band’s youth, the only characteristic sign of his TAB2 defi-
ciency was his hypermobility, whereas his sister had a
congenital heart defect that required surgical intervention.
Despite this, he ultimately presented with the most severe
phenotype of all family members having this pathogenic
variant. This case therefore supports the conclusion that
TAB2 deficiency can present in various degrees of severity
and at different stages of life, even within the same family.
In summary, we report on a novel pathogenic variant in a
large family leading to cardiomyopathy and other connective
tissue features with variable expression, and confirm the
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